

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JW (Cayman) Therapeutics Co. Ltd

藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

RESIGNATION OF DIRECTORS AND CHANGE OF COMPOSITION OF BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of JW (Cayman) Therapeutics Co. Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the below changes to the Board and the composition of the Board committees.

RESIGNATION OF DIRECTORS

The Board announces that, with effect from December 3, 2021, (i) Mr. Hans Edgar Bishop (“**Mr. Bishop**”) has resigned as a non-executive Director and a member of the remuneration committee of the Company (the “**Remuneration Committee**”); and (ii) Mr. Yanling Cao (“**Mr. Cao**”) has resigned as an independent non-executive Director and a member of the nomination committee of the Company (the “**Nomination Committee**”), due to their decisions to devote more time to their other commitments. Mr. Bishop will remain with the Company as a senior advisor.

Mr. Bishop and Mr. Cao has each confirmed that they have no claim against the Company and have no disagreement with the Board. In addition, there are no matters relating to their resignations that need to be brought to the attention to the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Bishop and Mr. Cao for their valuable contributions to the Company during their tenure of service.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

The Board further announces that, with effect from December 3, 2021, (i) Dr. Ann Li Lee, a non-executive Director, has been appointed as a member of the Remuneration Committee; and (ii) Mr. Kin Cheong Kelvin Ho, an independent non-executive Director, has been appointed as a member of the Nomination Committee.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Yiping James Li
Chairman

Shanghai, PRC, December 3, 2021

As at the date of this announcement, the Board comprises Dr. Yiping James Li as Chairman and executive Director, Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Chi Shing Li, Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho as independent non-executive Directors.

* For identification purposes only